Share on LinkedInShare on LinkedIn

ARTICLE · 22 DECEMBER 2012

Boehringer Ingelheim - A Welcome Decision for Pharmaceutical Brand Owners

Corrs Chambers Westgarth
Corrs Chambers Westgarth
Contributor
Corrs Chambers Westgarth

Corrs Chambers Westgarth

Corrs Chambers Westgarth is Australia’s leading independent law firm. We provide exceptional legal...

View firm profile
Explore more from Corrs Chambers Westgarth

Pharmaceutical brand owners have cause to celebrate following a recent decision.

AustraliaIntellectual Property

Pharmaceutical brand owners have cause to celebrate following a recent decision regarding the trade mark applications for marks incorporating INN stems in class 5.

Brand owners in the pharmaceutical space have cause to celebrate after a decision of Hearing Officer Ian Thompson, in the Boehringer Ingelheim case. The case involved a trade mark application for the mark ZELCIVOL in relation to pharmaceutical preparations in class 5.

As is commonly the case, the registry rejected the case on the basis that the mark contained an INN stem for goods that don't contain "phenols" or "alcohols". It was considered the mark would be likely to deceive or cause confusion.

Boehringer refused to enter an endorsement against its application and took the matter to a hearing. The Hearing Officer considered a number of arguments and particularly first looked at the current office practice at the Australian Trade Marks Office in relation to marks containing INN stems. The practice

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from